Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Fenaux

Showing results (141-150 of 432) with videos related to

Pageof 44
Sort By:
Leukemia Research|March 19, 2013
Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM)Cecile Bally, Sylvain Thépot, Bruno Quesnel, et al.
Leukemia Research Reports|July 29, 2014
An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromesStuart L Goldberg, Pierre Fenaux, Michael D Craig, et al.
Critical Reviews in Oncology/Hematology|May 11, 2010
Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromesJohn F Seymour, Pierre Fenaux, Lewis R Silverman, et al.
Cell Cycle (Georgetown, Tex.)|September 8, 2011
Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemiaSimone Boehrer, Lorenzo Galluzzi, Elodie Lainey, et al.
Leukemia Research|December 24, 2013
Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study modelPierre Fenaux, John F Seymour, Valeria Santini, et al.
Blood|September 25, 2008
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetMiguel A Sanz, David Grimwade, Martin S Tallman, et al.
British Journal of Haematology|January 29, 2014
Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromesJohn F Seymour, John M Bennett, Alan F List, et al.
Scientific Reports|July 3, 2025
Modeling mesenchymal stromal cell support to hematopoiesis within a novel 3D artificial marrow organoid systemBérénice Schell, Lin-Pierre Zhao, Inés M'Sibih, et al.
Blood|July 28, 2005
Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotypeNicolas Boissel, Aline Renneville, Valeria Biggio, et al.
The Journal of Clinical Investigation|May 4, 2011
Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemiaRomain Aucagne, Nathalie Droin, Jérôme Paggetti, et al.
Pageof 44

Showing results (141-150 of 432) with videos related to

Sort By:
Pageof 44
Leukemia Research|March 19, 2013
Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM)Cecile Bally, Sylvain Thépot, Bruno Quesnel, et al.
Leukemia Research Reports|July 29, 2014
An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromesStuart L Goldberg, Pierre Fenaux, Michael D Craig, et al.
Critical Reviews in Oncology/Hematology|May 11, 2010
Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromesJohn F Seymour, Pierre Fenaux, Lewis R Silverman, et al.
Cell Cycle (Georgetown, Tex.)|September 8, 2011
Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemiaSimone Boehrer, Lorenzo Galluzzi, Elodie Lainey, et al.
Leukemia Research|December 24, 2013
Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study modelPierre Fenaux, John F Seymour, Valeria Santini, et al.
Blood|September 25, 2008
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetMiguel A Sanz, David Grimwade, Martin S Tallman, et al.
British Journal of Haematology|January 29, 2014
Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromesJohn F Seymour, John M Bennett, Alan F List, et al.
Scientific Reports|July 3, 2025
Modeling mesenchymal stromal cell support to hematopoiesis within a novel 3D artificial marrow organoid systemBérénice Schell, Lin-Pierre Zhao, Inés M'Sibih, et al.
Blood|July 28, 2005
Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotypeNicolas Boissel, Aline Renneville, Valeria Biggio, et al.
The Journal of Clinical Investigation|May 4, 2011
Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemiaRomain Aucagne, Nathalie Droin, Jérôme Paggetti, et al.
Pageof 44